Oppenheimer Starts CTI BioPharma (CTIC) at Outperform

February 23, 2018 6:44 AM
Oppenheimer initiates coverage on CTI BioPharma (NASDAQ: CTIC) with an Outperform rating and a price target of $5.00.Analyst Leah Rush ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot New Coverage New Coverage